Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Clovis Oncology, Execs Fined Millions for Misleading Investors About Lung Cancer Drug

By Catherine Sbeglia | September 19, 2018

On Tuesday, The U.S. Securities and Exchange Commission (SEC) announced that Clovis Oncology, CEO Patrick Mahaffy, and former Chief Financial Officer Erle Mast have been instructed to pay more than $20 million in penalties to settle accusations of misleading investors about the company’s developmental lung cancer drug rociletinib.

Stephanie Avakian, co-director of the SEC’s enforcement division, commented, “”Biopharmaceutical companies cannot mislead investors about efficacy results,” adding that the available data should have alerted Clovis to “the inaccuracy of the claims about the effectiveness of its developmental drug.” 

The data in question was first revealed May 2015 when Clovis told investors that the recommended 500-mg dose of rociletinib, also known as Roci, resulted in tumor shrinkage in 60 percent of patients. However, despite Mahaffy and Mast eventually learning that the efficacy rate of the drug was 42 percent in July 2015, the company continued to report the 60 percent figure, including in stock offering materials.

Then in November 2015, Clovis released data that indicated a 28 percent effectiveness rate. According to the SEC, Clovis raised approximately $298 million in the stock offering, but saw its share price fall more than 70 percent following the disclosure of the latest efficacy rate.

An FDA advisory panel recommended against approval of rociletinib for the treatment of T790M-positive non-small-cell lung cancer in April 2016. The following month, Clovis ceased clinical development of the irreversible, mutant-selective EGFR inhibitor.

(Source: The U.S. Securities and Exchange Commission)

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE